Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Filings indexed 3,397 across all filing types
Latest filing 2020-01-27 Major Shareholding Noti…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
SEC SCHEDULE 13G
Major Shareholding Notification
2020-01-27 English
PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDP
Regulatory Filings
2020-01-27 English
ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN
Regulatory Filings
2020-01-27 English
BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKE
Regulatory Filings
2020-01-27 English
ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINES
Regulatory Filings
2020-01-27 English
Enhertu Phase II trial met primary endpoint
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 9767A' and is dated 27 January 2020. It details clinical trial results (Phase II DESTINY-Gastric01) for a drug (Enhertu) and includes quotes from management, safety profiles, and background information on the disease and the drug. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure and explicit source identification strongly indicate a regulatory news service announcement. Since the content is a substantive announcement of clinical trial results and business updates, it fits best under the general 'Regulatory Filings' category (RNS) as it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG). It is a general regulatory disclosure.
2020-01-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.